Cancers

Discover the connection between Non-Alcoholic Steatohepatitis (NASH) and cancer. Keep up-to-date with the latest research on risk factors, prevention, and management.

Obesity and liver cancer in Japan

It is estimated that there are more than 10 million NAFLD patients in Japan. 10-20% of NASH patients will progress to liver cirrhosis and 2-3% of them will develop hepatocellular carcinoma per year. In their review, H. Nishikawa et al. (Osaka Medical and Pharmaceutical University, Takatsuki, and Hyogo College of Medicine, Japan) comprehensively...
Read MoreObesity and liver cancer in Japan

The association between nonalcoholic fatty liver disease and esophageal, stomach, or colorectal cancer: National population-based cohort study.

The authors investigated the association between nonalcoholic fatty liver disease (NAFLD) and gastrointestinal tract cancer in the general population. Retrospective data on individuals aged ≥20 years who received healthcare checkups from January 1, 2009 to December 31, 2009 were analyzed using the National Health Insurance Database in Korea. NAFLD was defined...
Read MoreThe association between nonalcoholic fatty liver disease and esophageal, stomach, or colorectal cancer: National population-based cohort study.

Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer.

Here, the authors show that platelet number, platelet activation and platelet aggregation are increased in NASH but not in steatosis or insulin resistance. Platelet cargo, platelet adhesion and platelet activation...
Read MorePlatelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer.